Skip to main content
Oxford University Hospitals NHS Foundation Trust

Alert Coronavirus / COVID-19

If you have a new continuous cough, a high temperature, or a loss or change to your sense of taste or smell, do not come to our hospitals. Follow the national advice on coronavirus (COVID-19).

Please find information on our services and visiting restrictions in our COVID-19 section.

Patients and visitors must wear a face covering in our hospitals.

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Acute myeloid leukaemia (M80)

Molecular investigations

FLT3 internal tandem duplication and tyrosine kinase domain mutational analysis - targeted analysis for the FLT3 internal tandem duplication and variants within the FLT3 tyrosine kinase domain. Result has prognostic and treatment implications.

NPM1 insertion analysis- hotspot analysis for duplications and insertions within exon 12 of NPM1. Result has prognostic implications and can be used for monitoring minimal residual disease.

Myeloid panel (multi-target NGS panel (small variant)).

Minimal residual disease analysis - monitoring is available for various gene fusions and variants using q-PCR: CBFB-MYH11, RUNX1-RUNX1T1, BCR-ABL, PML-RARA, NPM1 variants.


As outlined in the Test Directory.


As outlined in the Test Directory other than tests M80.35, M80.37 & M80.40 - if any of these tests are required please contact us to discuss forwarding the sample elsewhere.

WGS for diagnostic samples

If there are tumour and germline samples available, along with appropriate consent, these will be forwarded to the WMRGL for further processing.

Last reviewed:02 August 2021